Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Moat Score: 0/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥39.30
GF Value ¥40.53
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Moat Score?

Tibet Rhodiola Pharmaceutical Holding Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Tibet Rhodiola Pharmaceutical Holding Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Tibet Rhodiola Pharmaceutical Holding Co might have No Moat - No discernible moat.

Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Tibet Rhodiola Pharmaceutical Holding Co Moat Score Related Terms

SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥39.30 is trading 3% below its estimated GF Value™ of ¥40.53. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Moat Score: 0
  • GF Value™: ¥40.53 vs. price of ¥39.30 (3% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥39.30
Price
¥40.53
GF Value